Breast Cancer Research and Treatment

, Volume 40, Issue 3, pp 265–270

Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer

Authors

  • Manuel Morales
    • Division of Medical OncologyHospital Nuestra Señora de la Candelaria
  • Norberto Santana
    • Department of Cellular and Molecular EndocrinologyUniversity Las Palmas G.C.
  • Adela Soria
    • Department of Clinical ChemistryHospital Insular
  • Alicia Mosquera
    • Department of Clinical ChemistryHospital Insular
  • José Ordovás
    • Lipid Metabolism LaboratoryUSDA Human Nutrition Research Center on Aging at Tufts University
  • Javier Nóvoa
    • Department of Clinical SciencesUniversity Las Palmas de G.C. Canary Islands
  • Pedro Betancor
    • Department of Clinical SciencesUniversity Las Palmas de G.C. Canary Islands
  • Pilar F. Valerón
    • Department of Cellular and Molecular EndocrinologyUniversity Las Palmas G.C.
  • Bonifacio Díaz-Chico
    • Department of Cellular and Molecular EndocrinologyUniversity Las Palmas G.C.
  • Ricardo Chirino
    • Department of Cellular and Molecular EndocrinologyUniversity Las Palmas G.C.
Report

DOI: 10.1007/BF01806815

Cite this article as:
Morales, M., Santana, N., Soria, A. et al. Breast Cancer Res Tr (1996) 40: 265. doi:10.1007/BF01806815

Abstract

Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%;P < 0.02), and in low-density lipoprotein cholesterol (17%;P < 0.01), and a significant 47 % increase in the subclass 2 of the high density lipoprotein cholesterol (P< 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein(a) (P< 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile.

Key words

apolipoproteinsbreast cancercardiovascular diseaselipoproteinslipoprotein(a)tamoxifen

Copyright information

© Kluwer Academic Publishers 1996